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Abstract
Background: Hepatocellular carcinoma (HCC) is the third most common cause of cancer related mortality worldwide. 9-
Nitrocamptothecin (9NC) is a potent topoisomerase-I inhibitor with strong anticancer effect. To increase the solubility and
stability, we synthesized a novel 9NC loaded liposomes (9NC-LP) via incorporating 9NC into liposomes. In the present study,
we determined the effects of 9NC and 9NC-LP on in vitro and in vivo, and the underlying mechanisms.
Methodology/Principal Findings: We first analyzed the characteristics of 9NC-LP. Then we compared the effects of 9NC and
9NC-LP on the proliferation and apoptosis of HepG2, Bel-7402, Hep3B and L02 cells in vitro. We also investigated their
anticancer properties in nude mice bearing HCC xenograft in vivo. 9NC-LP has a uniform size (around 190 nm) and zeta
potential (,211 mV), and exhibited a steady sustained-release pattern profile in vitro. Both 9NC and 9NC-LP could cause
cell cycle arrest and apoptosis in a dose-dependent and p53-dependent manner. However, this effect was not ubiquitous in
all cell lines. Exposure to 9NC-LP led to increased expression of p53, p21, p27, Bax, caspase-3, caspase-8, caspase-9 and
apoptosis-inducing factor, mitochondrion-associated 1 and decreased expression of Bcl-2, cyclin E, cyclin A, Cdk2 and cyclin
D1. Furthermore, 9NC-LP exhibited a more potent antiproliferative effect and less side effects in vivo. Western blot analysis
of the xenograft tumors in nude mice showed similar changes in protein expression in vivo.
Conclusions/Significance: In conclusion, 9NC and 9NC-LP can inhibit HCC growth via cell cycle arrest and induction of
apoptosis. 9NC-LP has a more potent anti-tumor effect and fewer side effects in vivo, which means it is a promising reagent
for cancer therapy via intravenous administration.
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Introduction
9-Nitrocamptothecin (9NC) is a potent topoisomerase-I inhibitor,
pharmacological studies disclosed that the antitumor activity of
9NC was superior to that of camptothecin (CPT) in human tumors
xenografted in nude mice [1]. The antitumor activity of 9NC closely
depended on its structure: the lactone form of 9NC was important to
its antitumor activity. However, the maintenance of the lactone form
is a challenge for the clinical application of 9NC. The applications of
9NC were also limited due to its poor solubility, instability and low
oral bioavailability [2,3]. The poor water solubility would induce
opsonization and cause rapid clearance in blood circulation after
intravenous injection [4]. Recently, several novel drug delivery
systems (DDS) have been used in 9NC tried to address problems
mentioned above, among the many DDS available, both micelles
and liposomes have gained the most attention [5,6].
Hepatocellular carcinoma (HCC) is the third most common
cause of cancer related mortality worldwide [7]. The incidence of
HCC has been increasing dramatically in the past decades and it is
expected to continue to increase for the next two decades [8,9]. In
2002, the incidence of HCC in Chinese male and female was
about 250,000 and 90,000, respectively (International Agency for
Research on Cancer: http://www-dep.iarc.fr/). In the United
States, primary liver cancer is projected to contribute more than
21,000 new cases and cause 18,000 deaths during 2008. HCC is
characteristic of progressive development and rapid metastasis.
Systemic therapy with cytotoxic agents has historically been of
marginal benefit. Exploration of more potential chemotherapeutic
agents is gaining increased attention [10].
To improve the stability and water solubility of 9NC, we con-
structed a novel liposome system containing 9NC via entrapping
9NC in liposomes with film-ultrasonic method. We then compared
the anticancer properties of 9NC and 9NC loaded liposomes (9NC-
LP) in vitro and in vivo. We also determined the effects of 9NC and
9NC-LP on the expression of several proliferation and apoptosis
related molecules to investigate the underlying mechanisms.
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Preparation of 9NC loaded liposomes and its releasing
characterization
The average size of 9NC loaded liposomes before and after
lyophilization was 160,200 nm, with a very narrow size dis-
tribution (Table 1). Encapsulation of 9NC slightly increased the
size of particles from 160 nm to 190 nm. There was no detectable
difference of the zeta potential (,211 mV) and encapsulation
efficiency (4.5%) of liposomes after lyophilization, which con-
firmed no degradation or aggregation occurred during the lyo-
philization and storage. As showed in SEM (Fig. 1A), 9NC
encapsulated liposomes was of regular spherical shape, while with
smaller size (,50 nm) than that detected by photon correlation
spectroscopy. It should be noted that the difference in the detected
sizes is due to the fact that photon correlation spectroscopy gives
the hydrodynamic diameter, while SEM shows the shape of dried
particles. The in vitro release of the 9NC loaded liposomes was
presented in Fig. 1B. The release time of the liposomes could last
for 600 minutes and the burst release is not obvious, which
implied that the hydrophobic 9NC was successfully encapsulated
in the liposomes.
Screening for in vitro growth inhibition
The compounds were first tested for their in vitro cytotoxicity via
MTT assay. As Table 2 shows HepG2 cell line consistently was
more sensitive in both 9NC and 9NC-LP, while Hep3B was
resistant to both drugs.
Cell Proliferation assay
To further determine the effects of 9NC and 9NC-LP on cell
proliferation, HepG2, Hep3B and L02 were subject to BrdU
proliferation assay. The proliferation of all cell lines was
suppressed after the treatment with 9NC and 9NC-LP. The
antiproliferative effects of both drugs were dose- and time-
dependent. As showed in Fig. 2 HepG2 cell line was more
sensitive in both 9NC and 9NC-LP. The results are similar to that
of the MTT assay.
Effects of the compounds on cell cycle arrest
9NC and 9NC-LP could induce apoptosis (increased Sub G1
peak) (p,0.05) and cause cell cycle arrest (p,0.05) of the HCC
cell lines. The effect is dose- and time-dependent in all tested
cell lines. Cell cycle phase is alternation according to the
compound concentration and incubation time in all test cell
lines. S phase delay was observed after exposure for 24 h and
G2/M phase delay was observed after exposure for 72 h in all
tested cell lines (Fig. 3A, Table S1). Both compounds caused
more significant cell cycle arrest in the HepG2 cells than in other
cell lines. Almost all of the HepG2 and Bel-7402 cells arrest in S
phase when compounds concentrations of both compounds were
over 0.05 mmol/L while L02 and Hep3B cells were more
resistant.
Induction of apoptosis
To confirm the effects of 9NC and 9NC-LP on cell apoptosis,
we next evaluated apoptosis induced by compounds on HepG2,
Hep3B and L02 via by FACSCalibur flow cytometry after the cells
stained with Annexin V-PE/7-AAD. As illustrated in Fig. 3B, both
the compounds induced apoptosis in a dose-dependent manner in
all tested cell lines. Similarly, the Hep3B cell line was less sensitive,
whereas HepG2 cell line was more sensitive. The results were in
accordance with the Sub G1 assay.
In vivo activity against human hepatocellular carcinoma
xenograft tumors
To determine the antitumor activity of 9NC and 9NC-LP in
vivo, we evaluated their effect in a nude mice xenograft model of
HepG2 cell line. Both reagents were administered at 1.5 mg/kg/d
or 2.5 mg/kg/d on a 5/2/5 (5 days on, 2 days off and 5 days on)
schedule for 3 weeks. The higher dose of (2.5 mg/kg/d)9NC-LP
inhibited tumor growth by about 87.02% on day 25, and the lower
dose (1.5 mg/kg/d) also inhibited tumor growth significantly
(41.66%; P,0.01) (Supplementary Tables 2). No significant loss
of body weight was observed when the mice were treated with
9NC-LP at the dose of 1.5 mg/kg/d, while significant weight loss
was detected at the dose of 2.5 mg/kg/d. However, there was
significant weight loss in mice treated with 9NC of both dose
groups. Furthermore, over half of the animals were killed by 9NC
at day 14 after administration of 2.5 mg/kg/d doses group. Body
weight loss, diarrhea, hemorhaging cystitis (hematuria) and
treatment-related death were observed in 9NC group while its
incidence is lower in 9NC-LP group (Fig. 4, Table 3, Table S2).
9NC and 9NC-LP affect expressions of proteins associated
with cell cycle progression and apoptosis
We then investigated the possible mechanisms responsible for
the effects of 9NC and 9NC-LP by evaluating its effects on the
expression level of various proteins involved in regulating cell cycle
progression and apoptosis. In both HepG2 and L02 compounds
activated p53; increased the expressions of p21, p27, Bax,
Caspase-3, Caspase-8, Caspase-9 and apoptosis-inducing factor,
mitochondrion associated 1 (AIFM1); decreased the expressions of
Bcl-2, cyclin A, CDK2, cyclin E and cyclin D1. In Hep3B cell, no
expression of p53 was detected and effects of compounds on cell
cycle-related and apoptosis-related proteins expression is less than
HepG2 and L02 cells. Interestingly, the patterns of protein
expression in the treated xenograft tumors were similar with those
observed in vitro (Fig. 5).
Discussion
This study was designed to evaluate the anticancer activities
of 9NC and 9NC-LP in vitro and in vivo human cancer models. We
have shown several important points: (a) the remarkable anti-
cancer activity of 9NC and 9NC-LP are dose- and cell type-
dependent; although cell cycle arrest is the major mechanism
responsible for the cytotoxicity of the compounds, apoptosis was
Table 1. Characteristics of 9NC encapsulated liposomes.
Size(nm) Zeta potential(mV) Encapsulation efficiency
Before lyophilization 162.469.4 211.569.5 4.660.2%
After lyophilization 199.669.8 211.567.1 4.563.1%
doi:10.1371/journal.pone.0021064.t001
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the expression of cell cycle-related, apoptosis-related proteins,
including p21, p27, Cdk2, Cyclin A, Cyclin E, Cyclin D1, Bcl-2,
Bax, Caspase-3, Caspase-8, Caspase-9 and AIFM1; (c) both 9NC
and 9NC-LP inhibited the growth of xenograft tumors in mice in a
dose-dependent manner, nevertheless 9NC-LP show an appar-
ently more potent antitumor effect and less side effect; and (d)
similar changes in protein expression were observed in vitro and in
vivo after exposure to compounds.
It is generally accepted that tumors have ‘leaky vasculature’ due
to endothelial gaps and irregular basement membranes [11].
Interendothelial gap defects increase vascular permeability in
tumors, leaky blood vessels would allow liposomes up to 400 nm
to passively accumulate the tumors at these sites [12], this property
is called the enhanced permeability and retention (EPR) effect
[13,14]. Our data shown 9NC-LP has a uniform size and less
negative potential. The release profile exhibited a steady sustained-
release pattern without obvious burst release. These characteristics
imply 9NC-LP suitable for intravenous administration.
Rapid release of drug from nanocarriers is still a challenge of
lipid-based vesicles; about 90% 9NC was released from liposomes
after 10 h in vitro in our study. Though there no obvious burst
release was observed, the rapid release means the formulation
needs more modifications to prolong its release time.
The present data showed that anti-proliferative effects were cell
type-dependent. In general, for both drugs, the order of sensitivity
was HepG2.Bel-7402.L02.Hep3B. The MTT assay results
indicated 9NC showed a stronger inhibitory effect after cells were
incubated for 10 h while 9NC-LP showed a stronger inhibitory
effect after cells were incubated for 48 h and 72 h; this can be
explained by the in vitro release profile of 9NC-LP, because 9NC
had not been released from liposomes completely after 10 h. Cell
cycle analysis showed that both drugs caused cell cycle arrest in
all cell lines. The ratio of S and G2/M phase cell increased
sequentially while the concentration and incubation time of the
reagents increased. This is prominent in HepG2 and Bel-7402 cell.
The ratio of Sub G1 population increased along with compound
concentration and incubation time increasing in all test cell lines.
The results of cell proliferation assay and detection of apop-
tosis are in accordance with MTT assay and Sub G1 method. The
present data showed that both the most common causes of
cell growth inhibition-cell cycle arrest and apoptosis [15] - were
involved in the anticancer activity of 9NC and 9NC-LP.
As an inhibitor of topoisomerase I, 9NC can attach to DNA and
form a ‘‘dead-end’’ complex which prevents topoisomerase-I from
resealing the DNA strand after the incision step [16]. This ‘‘dead-
end’’ complex causes DNA damage which can also cause growth
arrest and apoptosis. In this work, S and G2/M phase delay was
prominent, precise mechanism(s) must be extremely complicated.
Moreover, p53 plays a key role in the cell cycle delay; its effect is
involved in G1, S and G2/M phase arrest [17]. In mammalian
cells, the p53 tumor suppressor is usually responsible for the
growth arrest and apoptosis caused by DNA damage. Cdks
associate with cyclins to form heterodimers that are sequentially
Table 2. Cell growth inhibitory activity of 9NC and 9NC-LP in human cancer and normal cells.
Incubation time IC50(mmol/L)
a
HepG2 Bel-7402 Hep 3B L02
9NC 9NC-LP 9NC 9NC-LP 9NC 9NC-LP 9NC 9NC-LP
10 h 29.3961.26 37.5661.78 34.0560.95 46.861.39 346.36614.96 367.81620.33 39.9460.93 51.4362.45
24 h 16.3360.72 18.8160.89 17.4661.03 18.0060.94 275.15611.58 290.41618.71 17.8760.63 23.9060.36
48 h 6.2860.12 1.5360.08 6.8360.29 1.6160.04 17.1961.34 34.3961.52 29.1460.52 14.5260.48
72 h 0.1760.01 0.0260.00 0.4160.01 0.2960.01 7.2860.43 18.5660.52 12.5860.08 2.6660.05
aIC50, the concentration that inhibits cell growth by 50%.
doi:10.1371/journal.pone.0021064.t002
Figure 1. SEM image and in vitro release profile of 9NC loaded liposomes. (A) SEM image of 9NC loaded liposomes. (B) In vitro release profile
of 9NC from liposomes in pH 7.4-PBS at 3761uC by the dialysis method. The results are expressed as mean6SD (n=3).
doi:10.1371/journal.pone.0021064.g001
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pairs with E- and A-type cyclins during S phase. The the Cip/Kip
family (such as p21CIP1 [19] p27KIP1 [20]) can inhibit activity of
cyclin-Cdk heterodimers and cause phase-specific cell cycle arrest
[21]. Activated p53 can induce the expression of p21Cip1 which
can inhibit the S phase promoting factor (cyclin A-Cdk2 or cyclin
E-Cdk2 kinase complexes) , thereby causing a damaged cell to
arrest in S phase [22,23]. This is supported by the cell cycle profile
and activation of cell cycle-related proteins observed by western
blotting.
Apoptosis is also an important mechanism which is supported
by presence of Sub G1 peak in flow cytometry results and up-
regulation of apoptosis-related proteins in western blotting results.
The mammalian p53 can upregulate the expression of several
proapoptotic Bcl2-homology-domain proteins, such as Bax, which
can activate apoptosis [24]. In this study, mitochondrial apoptosis
pathway has also been observed which was supported by increase
of caspase-9, AIFM1, Bax and decrease of Bcl-2. Of note, apop-
tosis was observed at higher concentration and longer incuba-
tion time than cell cycle delay which indicate apoptosis appeared
relative late.
In our study, the p53-deficient cell Hep3B was more resistant to
drugs. This may be explained by the p53 activity. Usually, p53
have a very short half-life, its half-life can be extended by DNA
damage. Accumulation of p53 protein results in cell cycle arrest
and cell apoptosis. However, in p53-deficient cells, cell division is
not arrested despite the damage to DNA [25].
After evaluating the effects of the compounds on proliferation,
apoptosis, and cell cycle progression, we concluded that cell cycle
arrest was the main mechanism that 9NC exert its effects. The
modulation of cell-cycle progression in cancer is considered an
effective strategy to inhibit tumor growth [26]. The assumption
is based on a molecular analysis of human cancer, wherein cell
cycle regulators are frequently de-regulated in most of common
malignancies [27,28].
After our observation that 9NC and 9NC-LP exerted potent
effects against hepatocellular cancer cells in vitro, we initiated a
study to determine whether the compound could inhibit tumor
growth in a HepG2 xenograft model in vivo. As Fig. 4 indicates
9NC-LP shows an outstanding performance in vivo. A dose of
1.5 mg/kg/d and 2.5 mg/kg/d 9NC-LP for 3 weeks led to
41.66% and 87.02% tumor growth inhibition respectively, without
any drug-related death. Nevertheless, half of the animals were
killed at day 14 after administration in 2.5 mg/kg/d doses 9NC
group. Body weight loss, diarrhea, hemorhaging cystitis (hematu-
ria) and treatment-related death were observed in 9NC group
while its incidence is lower in 9NC-LP group. The present data
showed that liposomes delivery systems could improve the 9NC
antitumor activity while reduce the side effect. On the one hand,
this may because 9NC existed in active lactone/inactive car-
boxylate equilibrium, since the carboxylate form limited the anti-
tumor activity and increased the toxic side effects to normal tissues
[29]. Encapsulation of 9NC help to maintain the lactone that can
improve therapy effect and decrease side effects [30,31].On the
Figure 2. Cell proliferation inhibitory effects of 9NC and 9NC-LP on HepG2, L02 and Hep3B cells in vitro. Cell proliferation of HepG2(A),
L02(B) and Hep3B(C) cells was measured after exposure to compounds for 24–72 h. All assays were done in triplicate. The proliferation index is in
comparison with untreated cells (*P,0.01, P,0.05 vs. control) (There no significant differences between cells treated with 4%DMSO, Liposomes
(free) and untreated cells. Data not shown).
doi:10.1371/journal.pone.0021064.g002
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following reasons; due to the small size, liposomes readily extra-
vasate from circulation through vascular gaps or defects [32],
which have been reported to be ,200 nm or greater [12,33].
9NC-LP retention within these sites is generally high due to the
poor lymphatic drainage observed within tumors [34]. Further-
more, their lower size limit in diameter ensures that these vehicles
do not randomly penetrate normal vessel walls. As a result, 9NC-
LP minimizes the undesirable side effects which can occur using
conventional drugs [35,36].
Liposomal formulations of anticancer agents have already been
approved for human use. And the clinical success has made them
very popular drug carriers for various chemotherapeutics. For
example, the clinically approved drugs DaunoXome and Doxil
are liposomal formulations that encapsulate the commonly used
chemotherapeutic agents daunorubicin and doxorubicin respec-
tively [5].
Liposomes are composed of a phospholipid bilayer which
entirely surrounds an internal aqueous core. The liposomes bilayer
can be composed of either synthetic or natural phospholipids.
Liposomes are larger than micelles and therefore have the ability
to deliver greater amounts of the chemotherapeutic agent to the
tumor site while minimizing the risk associated with premature
leakage. In addition, liposomes also have the ability to accommo-
date both hydrophilic as well as hydrophobic drugs, either in the
internal aqueous core or in the lipid bilayer, respectively [37].
Otherwise, liposomes can easily be manipulated by adding addi-
tional molecules to the outer surface of the lipid bilayer.This offers
a significant advantage over other carriers that require much more
controlled synthesis steps and additional chemical modifications
[38]. When compared to conventional (unencapsulated) drugs,
liposomal treatment has been shown to dramatically reduce some
of the traditional side effects associated with chemotherapy [5]. It’s
noteworthy, liposomes was found own the potential to combat the
increasing problem of multidrug resistance (MDR) acquired by
cancers, which drastically reduces chemotherapeutic efficacy [39].
Liposomes have demonstrated multiple advantages as drug
delivery vehicles. However, lipid-based vesicles also pose several
challenges such as instability in the bloodstream, poor solubility of
many drugs in the lipid/surfactant solution, and a rapid, burst
release of drug.
To date, no specific in vivo study has compared the efficacy of
liposomes to that of other nanoparticle delivery systems; therefore,
we cannot comment on the relative efficacy of liposomes [39].
In conclusion, we have incorporated camptothecin analogues
into liposomes and synthesized a new 9NC formulation which
can be administered intravenously. 9NC-LP can inhibit HCC
growth via cell cycle arrest and apoptosis induction. Activation of
p53 may be one of the important regulators in 9NC-LP caused cell
death. More importantly, 9NC-LP has more potent effects and
fewer side effects in vivo. Further molecular, pharmacologic, and
toxicological studies are needed to elucidate the underlying
mechanisms and to determine the optimal dose. These studies
are important for further preclinical and clinical development of
this class of compounds.
Materials and Methods
In this study, the animal use and care protocol was approved
by the Institutional Animal Use and Care Committee of the
Huazhong University of Science and Technology (Permit
Number: 20090901).
Chemicals and reagents
9-nitrocamptothecin (9NC) was purchased from Hangzhou Heta
Pharm& Chem Co., Ltd. Cholesterol was from Aladdin reagent
(Shanghai, China). Egg yolk lecithin PC-98(egg yolk phosphatidyl-
choline) was obtained from Q.P. Corporation Fine Chemical
Figure 3. Cell cycle arrest and apoptosis-induced effects of 9NC and 9NC-LP on HepG2, L02 and Hep3B cells in vitro. For the cell cycle
analysis, cells were seeded at 2610
5 to 3610
5 per well in six-well paltes in triplicates and incubated with compounds. After treated for 24 h, 48 h and
72 h, cells were fixed, permeabilized, stained with PI and analyzed by flow cytometry. Results showed cells were incubated with 0, 0.01, 0.1, 1 mmol/L
9NC-LP for 24 h(A). Apoptosis of HepG2, L02 and Hep3B cells(B) was measured by flow cytometry after stained with AnnexinV-PE and 7-AAD
(Concentration: 0, 0.1, 1, 10 mmol/L). This experiment was done in triplicate and representative diagrams are shown (There no significant differences
between cells treated with 4%DMSO, Liposomes (free) and untreated cells. Data not shown).
doi:10.1371/journal.pone.0021064.g003
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analytic grade available. Cell culture supplies and media, PBS,
fetal bovine serum, and penicillin/streptomycin were obtained from
HyClone Thermo Fisher Scientific Inc. Anti-human Caspase-8,
Caspase-9, apoptosis-inducing factor, mitochondrion-associated
1(AIFM1) antibodies were from Proteintech Group, Inc. The
anti-human p53, p21, p27, Caspase-3, Bcl-2, Bax, cyclin A, cyclin
E, cyclin D1, cyclin-dependent kinase (Cdk)2 antibodies were from
Santa Cruz Biotechnology, Inc. 9NC was dissolved in dimethyl
sulfoxide (DMSO, Sigma-Aldrich, Germany) as a stock solution of
Figure 4. In vivo effects of 9NC and 9NC-LP given to nude mice bearing HepG2 xenograft tumors. Compounds were given i.v. at doses of
1.5 mg/kg/dor 2.5 mg/kg/d ona 5/2/5 (5days on,2 days offand5 days on) schedule for3 weeks.Tumor sizewas determinedevery twodayaftertumor
implantation. Tumor volume (cm
3)=(w
26l)/2, w=width, l=length of the tumor (A). (Values presents as means 6 SD. Liposomes (free): p.0.05; DMSO:
p.0.05; 9NC (1.5 mg/kg): p,0.05; 9NC-LP (1.5 mg/kg): p,0.05; 9NC-LP (2.5 mg/kg): p,0.01; vs. Saline respectively. The data of 9NC (2.5 mg/kg)
was removed from statistics for more than half animals were killed during the study). Animals were also monitored for changes in body weight every
three days after administration as a surrogate marker for toxicity (B). At the end of the experiment, representative tumors were removed and
photographed (C).
doi:10.1371/journal.pone.0021064.g004
Table 3. Toxicity of 9NC and 9NC-LP in human hepatocellular carcinoma xenograft tumor model.
Treatments body weight loss diarrhea hemorhaging cystitis(hematuria) treatment-related death
Liposomes(free) 0/10 0/10 0/10 0/10
4%DMSO 0/10 0/10 0/10 0/10
Saline 0/10 0/10 0/10 0/10
9NC 1.5 mg/kg 6/10 4/10 3/10 1/10
9NC-LP 1.5 mg/kg 2/10 0/10 0/10 0/10
9NC
a 2.5 mg/kg 10/10 10/10 10/10 6/10
9NC-LP 2.5 mg/kg 10/10 4/10 1/10 0/10
All animals were monitored from day 1 to day 27 after administration, the animal was defined as positive once item appearance. The values presented the total number
of item positive animals in the 10 mice in each group.
aIn this group, 6 mice were dead caused by treatment on day 14 after administration, the others were sacrificed and tumors were removed for the protein expression
analysis on the same day.
doi:10.1371/journal.pone.0021064.t003
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4%DMSO(thehighestconcentrationusedtodilutethe 9NCinthis
study) and liposome without any 9NC were included in all assays
as control group.
Preparation and characterization of 9NC loaded
liposomes
9NC loaded liposomes were prepared by classic film-ultrasonic
method. Briefly, the lipid mixture (phosphatidylcholine: cholester-
ol=2:1, w/w) and 9NC (with drug to phosphatidylcholine=1:5,
w/w) were dissolved in appropriate mixture solution of dichloro-
methane and methanol (3:1, v/v), and a thin lipid film was formed
by rotary evaporating at 40uC under reduced pressure. Resulted
dried lipid film was vacuum-dried overnight to get rid of residual
organic solvent. Then the film was hydrated in 8 mL of D-Hanks
solution (0.01 M, pH 6.5) with 9NC. Subsequently, the suspen-
sion was sonicated in an ice bath to clarity. After preparation,
unencapsulated free 9NC were separated by ultrafiltration, and
the encapsulation efficiency was calculated according to previous
study [40]. The mean particle size (z-average) of liposomes was
measured by photon correlation spectroscopy (Nano ZS90;
Malvern, UK). A 1:100 dilution of the formulations was made
using double-distilled water before the zeta potential measure-
ment. Morphology of the liposomes was characterized by scan
electron microscopy (SEM).
Release and lyophilization of liposome
Release of camptothecin from the drug carrier systems was
measured using dialysis method with a molecular weight cut-off
of 10, 000 Da. The receptor medium consisted of isotonic
phosphate buffer solution (137 mM NaCl, 3 mM KCl, 8 mM
Na2HPO4, 1 mM KH2PO4, pH 7.4) containing 0.05% Tween
80, which was constantly stirred at 3761uC in order to maintain
sink conditions during the experiments [40]. At appropriate inter-
vals, 1 mL aliquots of the receptor medium were withdrawn and
immediately replaced with an equal volume of fresh buffer. The
amount of drug released was determined by UV. A certain
amount of D-trehalose was added into freshly prepared liposomes
for freeze-dry in Eppendorf tubes with final concentration of 1.2%.
Before lyphilization, solution was sterilized by filtering through
0.22 mmol/L membrane. The tubes were prefrozen at 280uC for
24 h, and placed into the drying chamber of the Freeze Dry
Figure 5. Effects of drugs on the expression of proteins related to cell cycle progression and apoptosis in human hepatocellular
carcinoma cell line and normal liver cell line. In vitro, HepG2, L02 and Hep3B cells were exposed to the compound (1 mmol/L) for 24 h; then
target proteins were examined by western blotting(A). In vivo, compounds were given i.v. at doses of 1.5 mg/kg/d or 2.5 mg/kg/d on a 5/2/5 (5 days
on, 2 days off and 5 days on) schedule for 3 weeks. The expression of proteins from tumor homogenates was analyzed by western blotting (B).
doi:10.1371/journal.pone.0021064.g005
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24 h-drying performance. Physicochemical properties of lyophi-
lized liposomes were investigated, including size, surface charge
and entrapment efficiency.
Cell culture
The HepG2, Bel-7402 and Hep3B human HCC cell lines and
L02 normal liver cell line was involved in this study. HepG2 and
L02 were obtained from the China Center for Type Culture Col-
lection. Bel-7402 purchased from the cell bank of Chinese Academy
of Science. Hep3B is a p53-deficient human HCC cell line and was
obtained from American Type Culture Collection [41,42]. HepG2
and L02 were routinely passaged in DMEM (High Glucose) Media
while Bel-7402 was passaged in RPMI 1640 media. Hep3B was
passaged in MEM media. All cell culture media contained 10%
fetal bovine serum and 1% penicillin/streptomycin. Cultures were
maintained at 37uC in the presence of 5% CO2.
Cell survival assay
The effects of the test compounds on cell viability were
determined with the use of the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) assay. Cells were seeded in
96-well plates at 4610
3 to 5610
3 cells per well and exposed to
different concentrations of the test compounds (0, 0.001, 0.01, 0.1,
1, 10, or 100 mmol/L). After incubation for 10 h, 24 h, 48 h and
72 h, 10 mL of the MTT solution (5 mg/mL; Sigma) were added
into each well. The plates were incubated for further 4 h at 37uC.
Thereafter, the supernatant was removed, and the formazan
crystals were dissolved with 100 mL of DMSO. The absorbance
at 490 nm was recorded with the use of a microplate reader
(Molecular Devices).
Cell proliferation assay
To further determine the effects of 9NC and 9NC-LP on cell
proliferation, cell proliferation ELISA assay (BrdU (colorimetric);
Roche Diagnostics) was used in this study. HepG2, Hep3B and
L02 cells were seeded in 96-well plates at a density of 4610
3 to
5610
3 and incubated with 9NC and 9NC-LP (0, 0.001, 0.01, 0.1,
1, 10, or 100 mmol/L) for 24, 48 and 72 h. The determination of
the cell proliferation was carried out according to the manufac-
turer’s instruction manual. The mean absorbance of the untreated
wells was defined as 100%; absorbance of the other wells was then
related to this value.
Cell cycle measurements and Sub G1 FACS assay
Cells (2610
5 to 3610
5) were exposed to the test compounds
(0, 0.01, 0.025, 0.05, 0.1, 0.5, 1, or 10 mmol/L) and incubated for
24 h, 48 h and 72 h before analysis. The cells were harvested and
fixed in 70% ethanol at 220uC overnight, followed by incubation
with RNase and staining with propidium iodide (Sigma-Aldrich,
Germany). The DNA content was determined by FACSCalibur
flow cytometer (Becton Dickinson Biosciences, San Jose, CA).
Detection of apoptosis
HepG2, Hep3B and L02 cells in early and late stages of
apoptosis were detected using of an Annexin V-PE/7-AAD
apoptosis detection kit from KeyGEN according to the manufac-
turer’s protocol. 2610
5 to 3610
5 cells were exposed to the test
compounds (0, 0.1, 1, 10 mmol/L) for 24 h before analysis. The
cells were collected and washed with serum-free media, then
resuspended in binding buffer followed by the addition of 5 mL
of Annexin V-PE and 5 mL of 7-AAD. The samples were incu-
bated in the dark and were analyzed with a Becton Dickinson
FACSCalibur instrument. The cells that were positive for Annexin
V- PE alone (early apoptosis), and Annexin V- PE and 7-AAD
(late apoptosis) were counted.
Human xenograft models and animal treatment
Female athymic pathogen-free nude mice (BALB/c, 3–4 wk)
were purchased from Shanghai SLAC laboratory Animal Co.,
Ltd. (SLAC). To establish HepG2 human hepatocellular cancer
xenograft tumors, HepG2 cells were harvested from monolayer
cultures, washed twice with serum-free medium, resuspended, and
injected s.c. (1610
7 cells; total volume, 0.2 mL) into the backs area
of the mice. Ten days after implantation, mice were randomly
sorted into treatment groups (10 mice in each group) and were
administrated intravenously (i.v.) via tail vein with saline, 9NC-LP
(1.5 mg/kg/d), 9NC-LP (2.5 mg/kg/d), 9NC (1.5 mg/kg/d) and
9NC (2.5 mg/kg/d). Mice were treated i.v. (0.2 mL/20 g body
weight) with drugs on a 5/2/5 (5 days on, 2 days off and 5 days on)
schedule. Tumor size was determined every two day by caliper
measurement of two perpendicular diameters of the implant. Body
weight was monitored every three days during the studies. All
animals were monitored for activity, physical condition, body
weight, and tumor growth. Animals were sacrificed on day 27 after
administration; tumors were removed for the protein expression
analysis.
Western blot analysis
The protein levels in cell lysates and tissue homogenates were
assessed with the use of methods described previously [43]. In the
in vitro studies, cells were exposed to of 1 mmol/L 9NC and 9NC-
LP. Western blot experiments were carried out by regular SDS-
PAGE. Cell lysates with identical amounts of protein were
fractionated and transferred to Immobilon
TM PVDF Transfer
Membranes (Millipore). The PVDF membrane was incubated in
blocking buffer (TBS containing 0.1% Tween 20 and 5% nonfat
milk) for 2 h at room temperature. Then the membrane was
incubated with the appropriate primary antibody overnight at 4uC
or 2 h at room temperature with gentle shaking. The membrane
was washed and then incubated with goat anti-mouse/rabbit
IgG-horseradish peroxidase-conjugated antibody (Santa Cruz
Biotechnology, Inc.) for 1 h at room temperature. After repeating
the washes in triplicate, the protein of interest was detected by
enhanced chemiluminescence reagents from Pierce, Thermo
Fisher Scientific Inc..
Data and statistical analysis
Experimental data are expressed as mean 6 standard devia-
tion(SD), and the significance of differences was analyzed by
Repeated Measures Analysis of Variance, one-way analysis of
variance (ANOVA), Multi-factor Analysis of Variance and post
hoc test or Student’s t test as appropriate.
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